Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction.

We showed the dose-dependent growth inhibition by alltrans retinoic acid (ATRA) of myeloma cells freshly isolated from patients. ATRA downregulated the cell surface expression of interleukin-6 receptor (IL-6R) and/or glycoprotein (gp) 130. The growth-inhibitory activity of ATRA was well correlated with that of anti-gp 130 antibody in every sample. Furthermore, ATRA inhibited the production of IL-6 from both myeloma cells and marrow stromal cells, and recombinant IL-6 (rIL-6) could partially recover the myeloma cell growth that had been inhibited by ATRA. These data suggest that ATRA may inhibit the proliferation of myeloma cells both by the downregulation of IL-6R and gp130 expression on myeloma cells and by the inhibition of IL-6 production from myeloma and stromal cells. Prednisolone (PSL) and interferon-gamma (IFN-gamma) also inhibited the myeloma growth, while their effects were different from those of ATRA on IL-6 R and gp130 expression, IL-6 production, and morphological change. The inhibitory effect of ATRA on myeloma cell proliferation was observed in 10 of 14 samples obtained from eight patients, which suggests that ATRA may be a potent new therapeutic agent for some myeloma patients.

[1]  U. Rao,et al.  Biological response modifiers. , 2004, Seminars in oncology.

[2]  B. Klein,et al.  Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130 , 1994, The Journal of experimental medicine.

[3]  Y. Shima,et al.  Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130 , 1994, The Journal of experimental medicine.

[4]  K. Anderson,et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.

[5]  K. Yasukawa,et al.  Preparation of monoclonal antibodies against the IL-6 signal transducer, gp130, that can inhibit IL-6-mediated functions. , 1993, Journal of immunological methods.

[6]  G. Eichele.  Retinoids in Embryonic Development a , 1993, Annals of the New York Academy of Sciences.

[7]  A. Ross,et al.  Overview of retinoid metabolism. , 1993, The Journal of nutrition.

[8]  T. Hirano,et al.  Human bone marrow stromal cell lines from myeloma and rheumatoid arthritis that can support murine pre-B cell growth. , 1992, Journal of immunology.

[9]  E. Smeland,et al.  Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cells. , 1992, The Journal of biological chemistry.

[10]  B. Klein,et al.  Interleukin‐6 dependence of advanced malignant plasma cell dyscrasias , 1992, Cancer.

[11]  A. Myc,et al.  Differences in the action and metabolism between retinol and retinoic acid in B lymphocytes , 1991, The Journal of cell biology.

[12]  L. M. Luca,et al.  Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. , 1991 .

[13]  M. Jourdan,et al.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.

[14]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[15]  T. Hirano,et al.  Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. , 1991, Journal of immunology.

[16]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[17]  A. Ross.  Vitamin A: Current Understanding of the Mechanisms of Action , 1991 .

[18]  T. Hirano,et al.  Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.

[19]  R Berger,et al.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.

[20]  T. Hirano,et al.  Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. , 1989, Journal of immunology.

[21]  C. Morimoto,et al.  Response patterns of purified myeloma cells to hematopoietic growth factors. , 1989, Blood.

[22]  M. Jourdan,et al.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. , 1989, Blood.

[23]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[24]  H. Asaoku,et al.  Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro. , 1988, Blood.

[25]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[26]  S. Collins,et al.  Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Klein,et al.  gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. , 1993, Blood.

[28]  M. Kurimoto,et al.  A new highly sensitive immunoassay for cytokines by dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). , 1992, Journal of immunological methods.